There was a phase-2 trial by Roussel et.al in Blood 2010
[Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) ]
which showed CR was higher if velcade was added. But I couldn't find any data on long term outcomes. Is there any data on this?
Hi Ashok,
Although I think that the real answer to this question will require a proper systematic review, however, for the start I suggest a simple search for trials, then check the results and then either contact the researchers of relevant trials or search the relevant trials registry number for possible publications online:
1. ClinicalTrials.gov
2. apps.who.int/trialsearch/
3. ISRCTN.com
I ran a simple search in the first one and here are the results:
https://clinicaltrials.gov/ct2/results?term=multiple+AND+myeloma+AND+bortezomib+AND+autologous+AND+stem+AND+cell+AND+transplantation
Little evidence of added efficacy at this point.
Would be surprising that 1-2 Bortezomib doses would add efficacy over many previous doses pre-transplant + high-dose melphalan.
Randomized trial ongoing at IFM.